

Osteoporosis

Referral for Medication and Patient Management Program



Phone: 877.385.0535

Fax: 877.326.2856

6480 Technology Ave., Suite A | Kalamazoo, MI 49009

Please fax a copy (front and back) of all the patient's pharmacy and medical insurance cards as well as any relevant clinical notes/documents

| Patient Demographics | | Provider Information | |
|--|--|---|--|
| Name _____ Sex <input type="checkbox"/> M <input type="checkbox"/> F | | Prescriber _____ | |
| DOB _____ SSN _____ | | NPI _____ DEA _____ | |
| Phone _____ 2 nd Phone _____ | | Practice Name _____ | |
| Address _____ Apt/Suite _____ | | Address _____ | |
| City, State, ZIP _____ | | City, State, ZIP _____ | |
| Primary language, if other than English _____ | | Phone _____ Fax _____ Key contact _____ | |
| This is a <input type="checkbox"/> New Rx <input type="checkbox"/> Refill | Training by <input type="checkbox"/> Prescriber's office <input type="checkbox"/> Not needed <input type="checkbox"/> Pharmacy to facilitate | Ship to / Site of Care <input type="checkbox"/> Prescriber's office <input type="checkbox"/> Patient (Forteo and Tymlos only) <input type="checkbox"/> OptiMed Infusion Center <input type="checkbox"/> Other _____ | |

| Clinical Information | |
|---|---|
| Diagnosis (include ICD-10 code) _____ | BMD/T-score _____ Date _____ |
| Weight _____ <input type="checkbox"/> lb <input type="checkbox"/> kg Height _____ <input type="checkbox"/> in | Serum calcium level** _____ Date _____ |
| Allergies _____ | Is patient at risk for osteoporotic fracture as evident by any of the following? |
| _____ Latex allergy? <input type="checkbox"/> Yes <input type="checkbox"/> No | <input type="checkbox"/> History of osteoporotic fracture Site _____ Date _____ |
| Prior treatments & reason for discontinuation _____ | <input type="checkbox"/> Patient has tried and failed oral bisphosphonate |
| _____ | <input type="checkbox"/> Patient has documented contraindication/is intolerant to oral bisphosphonate therapy |
| _____ | <input type="checkbox"/> Other _____ |
| *Please submit a copy of DEXA and serum calcium level with prescription* | |

| | Medication | Directions | Quantity | Refills | |
|--|--|--|---|---------|-------|
| Antiresorptive | <input type="checkbox"/> Prolia® 60mg * (denosumab) | Inject 60mg subcutaneously every 6 months. | 1 syringe (180-day supply) | _____ | |
| <i>Administration by a healthcare professional only. Ship to Provider Office or administer at OptiMed Ambulatory Infusion Center as indicated above.</i> *Serum Calcium level required within 30 days of onsite injection. | | | | | |
| Anabolic | <input type="checkbox"/> Evenity™ 105mg * (romosozumab-aqqg) | Inject 210mg (2 syringes) subcutaneously once monthly. **Limit duration of use to 12 monthly doses** | 2 syringes (30-day supply) | _____ | |
| | <i>Administration by a healthcare professional only. Ship to Provider Office or administer at OptiMed Ambulatory Infusion Center as indicated above.</i> *Serum Calcium level required within 30 days of onsite injection. | | | | |
| | <input type="checkbox"/> Forteo® multi-dose pen (teriparatide) with pen needles | Inject 20mcg subcutaneously once daily. Use a new pen needle daily for Forteo® injection. | 1 pen (28-day supply) 1 box (30 needles) | _____ | _____ |
| <input type="checkbox"/> <i>Check here to enroll the patient into Forteo® Connect ongoing support.</i> | | | | | |
| <input type="checkbox"/> Tymlos® multi-dose pen (abaloparatide) with pen needles | Inject 80mcg subcutaneously once daily. Use a new pen needle daily for Tymlos® injection. | 1 pen (30-day supply) 1 box (30 needles) | _____ | _____ | |

Other Medication

Drug _____ _____ _____

Please note: To increase adherence and patient acceptance all medications will be dispensed as pen type injectors unless unavailable or otherwise specified.

Provider Signature _____ **Date** _____

My signature for this prescription confirms that the treatment(s) indicated on this referral is/are medically necessary. I authorize OptiMed and its representatives to act as an agent of mine to initiate and execute the patient's insurance prior authorization process and to provide administrative nursing services and supplies if necessary, in conjunction with the therapy prescribed above.

V121919A

Confidentiality statement: This message is intended only for the individual or institution to which it is addressed. This may contain information, which is confidential, privileged, and/or proprietary. This information may be exempt from disclosure under applicable laws including but not limited to HIPAA. If you are not the intended recipient, please note you are strictly prohibited from distributing, copying, or disseminating this information. If you received this information in error, please notify the sender noted above and destroy all transmitted material.